Sutro Biopharma (NASDAQ:STRO - Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($2.96) EPS for the quarter, missing the consensus estimate of ($0.86) by ($2.10), RTT News reports. Sutro Biopharma had a negative return on equity of 101.89% and a negative net margin of 77.01%. The company had revenue of $14.00 million during the quarter, compared to analysts' expectations of $10.44 million. During the same quarter last year, the business earned ($1.78) earnings per share.
Sutro Biopharma Trading Up 15.1 %
NASDAQ:STRO traded up $0.12 during mid-day trading on Monday, reaching $0.93. The company's stock had a trading volume of 7,095,302 shares, compared to its average volume of 956,082. The firm's fifty day moving average price is $1.75 and its two-hundred day moving average price is $2.72. The stock has a market cap of $76.88 million, a P/E ratio of -0.58 and a beta of 1.22. Sutro Biopharma has a 12-month low of $0.77 and a 12-month high of $6.13.
Analyst Ratings Changes
STRO has been the topic of several research reports. Wells Fargo & Company dropped their price target on Sutro Biopharma from $5.00 to $4.00 and set an "equal weight" rating on the stock in a research report on Wednesday, December 11th. HC Wainwright reaffirmed a "neutral" rating and set a $2.00 target price (down previously from $12.00) on shares of Sutro Biopharma in a research note on Monday. JMP Securities reissued a "market outperform" rating and issued a $17.00 price target on shares of Sutro Biopharma in a research report on Wednesday, December 11th. Citizens Jmp downgraded Sutro Biopharma from an "outperform" rating to a "market perform" rating in a research note on Friday. Finally, Wedbush cut Sutro Biopharma from an "outperform" rating to a "neutral" rating and lowered their price objective for the company from $8.00 to $2.00 in a research note on Friday. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Hold" and an average target price of $7.75.
View Our Latest Analysis on Sutro Biopharma
About Sutro Biopharma
(
Get Free Report)
Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.
Featured Stories
Before you consider Sutro Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sutro Biopharma wasn't on the list.
While Sutro Biopharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
